WO2024150190 - COMPOSITIONS AND METHODS FOR TREATING CYSTITIS
National phase entry:
Publication Number
WO/2024/150190
Publication Date
18.07.2024
International Application No.
PCT/IB2024/050334
International Filing Date
12.01.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING CYSTITIS
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA CYSTITE
Applicants **
FERRING B.V.
Polaris Avenue 144
2132 JX Hoofddorp, NL
Inventors
PADHI, Bijay Kumar
c/o Ferring Pharmaceuticals Pvt. Ltd.
Ferring Hyderabad Product Development Centre,
Plot No. 14, TSIIC Biotech Park, Phase II Extn,
Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt)
Hyderabad 500 101, IN
BAHETI, Ankit
c/o Ferring Pharmaceuticals Pvt. Ltd.
Ferring Hyderabad Product Development Centre,
Plot No. 14, TSIIC Biotech Park, Phase II Extn,
Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt)
Hyderabad 500 101, IN
ZODE, Sandeep Suresh
c/o Ferring Pharmaceuticals Pvt. Ltd.
Ferring Hyderabad Product Development Centre,
Plot No. 14, TSIIC Biotech Park, Phase II Extn,
Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt)
Hyderabad 500 101, IN
Priority Data
202311002763
13.01.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1691 | |
| EPO | Filing, Examination | 11653 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5710 |
Total: 20220 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.[French]
L'invention concerne des compositions pharmaceutiques aqueuses comprenant de la lidocaïne, de l'acide hyaluronique et du sulfate de chondroïtine (ou des sels pharmaceutiquement acceptables de l'un quelconque de ceux-ci) et de l'eau, ainsi que des procédés de fabrication de telles compositions pharmaceutiques aqueuses, et des méthodes thérapeutiques y faisant appel.